DRI Healthcare TrustDHT-UN.TO

Health Care · Pharmaceuticals, Biotechnology & Life Sciences · TSX · Canada · drihealthcare.com

DRI Healthcare Trust is a Toronto-headquartered trust focused on acquiring and managing a portfolio of pharmaceutical royalties, providing capital to biopharmaceutical innovators in exchange for royalty interests in marketed medicines. Its portfolio includes royalties on drugs such as Eylea, Orserdu, Spinraza, Vonjo and Zytiga. Its units trade on the Toronto Stock Exchange in Canadian dollars as DHT.UN and in U.S. dollars as DHT.U.

Key ratios

Operating cash flow growth

-27.2%TTM

2025 -29.3%2024 103.5%2023 -0.6%

EPS growth

-57.7%TTM

2023 632.1%

FCF / Sales

54.3%TTM

2025 56.8%2024 83.1%2023 45.9%

Net margin

-26.3%2025

2024 -1.8%2023 55.0%

ROA

3.5%2025

2024 3.2%2023 1.7%

ROE

-10.4%TTM

2025 -10.5%2024 -0.6%2023 19.7%

Revenue growth

5.9%TTM

2025 2.6%2024 12.5%2023 78.7%

Recent news

DRI Healthcare Announces Receipt of Put Price on EKTERLY 2026-08-11 · CNW DRI Healthcare Reports Second Quarter 2026 Results and New Board Appointment 2026-08-07 · CNW DRI Healthcare Announces Exercise of Put Option on EKTERLY® 2026-07-10 · CNW

Track DHT-UN.TO in your journal

Save it to a watchlist, run a reverse DCF, and keep your notes on the company in one place. Free to start.

Create a free account

Figures are sourced from third parties and shown for research only. They may be delayed or incomplete, and nothing on this page is investment advice or a recommendation to buy or sell. Read the full disclaimer